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Group B  
Streptococcus  
Meningitis in Child 
with Cochlear  
Implant
To  the  Editor:  Streptococcus   
agalactiae, designated group B strepto-
coccus (GBS), is a major cause of in-
fections in neonates and young infants 
(1). Invasive GBS disease in children 
beyond infancy is uncommon, occur-
ring  mainly  as  bacteremia  without  a 
focus;  meningitis  caused  by  GBS  is 
rarely  reported  (2).  Cochlear  implant 
recipients  have  been  documented  as 
having a higher rate of postimplantation 
bacterial meningitis than a cohort of the 
same age in the general US population 
(3). However, no cochlear implant re-
cipient described has been reported to 
be infected with GBS. We report a case 
of GBS meningitis in a 6-year-old boy 
with a cochlear implant.
The  patient  was  hospitalized  in 
2007  with  a  1-day  history  of  fever, 
headache,  and  vomiting.  His  medi-
cal history indicated congenital bilat-
eral  deafness  diagnosed  at  1  month 
of age and consistent with Patterson 
syndrome (i.e., unusual facies, deaf-
ness,  bronzed  hyperpigmentation  of 
the  skin,  cutis  laxa,  mental  retarda-
tion, and bony deformities) (4). At 4 
years of age, he received a right-ear 
cochlear implant with good functional 
result.  Preoperative  high-resolution 
computed tomography of the tempo-
ral  bones  showed  bilateral  inner  ear 
malformations  of  both  the  cochlear 
and  vestibular  labyrinth,  conditions 
consistent with bilateral Mondini de-
formity (5). Mastoids and middle ears 
were well aerated. No evidence of ce-
rebrospinal fluid leak appeared during 
physical examination or imaging. He 
received a dose of 23-valent pneumo-
coccal polysaccharide vaccine.
At  the  time  of  hospital  admis-
sion, he was somnolent but could be 
aroused and was cooperative. He had 
nuchal  rigidity,  dysmorphic  facies, 
and  oligodactyly.  Fundi,  skin,  and 
ears were unremarkable on examina-
tion. Lumbar puncture showed a total 
protein level of 204 mg/dL, a glucose 
level of 1.6 mmol/L (blood glucose 3 
mmol/L), and 4,800 leukocytes/mm3 
with  88%  neutrophils;  no  bacteria 
were seen on the Gram stain. Blood 
count  was  remarkable  for  leukocy-
tosis  of  30,000/mm3  and  neutrophil 
predominance.
The  patient  received  treatment 
with  dexamethasone,  vancomycin, 
and  ceftriaxone;  after  treatment,  his 
condition  improved  rapidly.  Blood 
culture was sterile, but GBS grew in 
the  cerebrospinal  fluid  culture  (the 
isolate  being  resistant  only  to  tetra-
cycline). Therapy was continued with 
ampicillin for 3 weeks. Repeated test-
ing of his hearing and speech percep-
tion with the cochlear implant showed 
no deterioration.
GBS plays a major role in early- 
and late-onset infections in neonates 
and  young  infants  (1).  Infections  in 
older children and adults have been de-
scribed, especially in elderly patients 
or those suffering from chronic condi-
tions such as diabetes mellitus, malig-
nancy, or HIV infection (6). A review 
of  medical  records  of  patients  with 
GBS infections over a 7-year period 
at a children’s hospital in Memphis, 
Tennessee, USA, showed that, among 
18 patients >3 months of age (13% of 
all GBS infections in the study), bac-
teremia was most commonly reported; 
3 cases of ventriculo-peritoneal shunt 
infections were recorded, but no cases 
of meningitis without foreign devices 
were  found  (2).  GBS  meningitis  in 
children beyond infancy is rare; only a 
few cases have been reported (7).
Cochlear  implantation  is  the 
standard  treatment  for  children  and 
adults affected by severe and severe-
to-profound  sensorineural  hearing 
loss. The implant is a neural stimula-
tor with an electrode array surgically 
placed near the auditory nerve fibers 
in the scala tympani of the cochlea. 
Pediatric  cochlear  implant  recipients 
were  found  to  be  at  higher  risk  for 
developing  bacterial  meningitis  than 
children in the general US population 
(3). Increased risk was evident in the 
perioperative period but extended to 
>2  years  postimplantation  (8).  Most 
meningitis cases were associated with 
an implant with a positioner, a silastic 
wedge inserted next to the implanted 
electrode in the cochlea to position the 
electrode closer to the cochlear nerve 
endings  and  thus  facilitate  electrical 
signal transmission. Most of those in-
fections were caused by Streptococcus 
pneumoniae, and none by GBS (3,8). 
In our patient, the implant did not in-
clude a positioner. The timing of men-
ingitis was consistent with the timing 
indicated in previous reports, but the 
infecting organism was unique.
Inner  ear  malformations  them-
selves  are  associated  with  increased 
risk  for  meningitis  (9).  The  patient 
reported here had bilateral inner ear 
malformations;  therefore,  estimating 
the relative role of the deformity com-
pared with the cochlear implant’s role 
in  the  pathogenesis  of  meningitis  in 
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his case is difficult. Meningitis in pa-
tients with inner ear malformations is 
associated with bacteria (e.g., S. pneu-
moniae and Haemophilus influenzae) 
that colonize the upper airways. The 
prevalence of oropharyngeal coloniza-
tion with GBS is low (≈5%), explain-
ing the rarity of GBS meningitis (10). 
Unlike for pneumococcal meningitis, 
which can be prevented at least par-
tially  by  vaccination,  no  vaccine  is 
available for GBS.
Our report adds another example to 
the growing spectrum of invasive GBS 
disease  beyond  infancy.  GBS  is  uni-
formly susceptible to penicillin; there-
fore,  treatment  directed  at  common 
causes of bacterial meningitis is also 
appropriate for GBS (1,10). Cochlear 
implant  recipients  with  symptoms  of 
fever, otitis media, or headache should 
be carefully assessed; if meningitis is 
diagnosed, GBS should be considered 
as a possible causative organism.
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Severe Necrotizing  
Pneumonia in  
Children, Houston, 
Texas, USA
To  the  Editor:  Routine  vacci-
nation  of  children  with  the  7-valent 
pneumococcal  conjugate  vaccine 
(PCV-7; Wyeth Pharmaceuticals, Col-
legeville,  PA,  USA),  initiated  in  the 
United States in 2000, was followed 
within  2  years  by  an  extensive  and 
rapid decline in invasive pneumococ-
cal disease (IPD) (1). During the past 
few years, increasing frequency of in-
vasive  disease  including  necrotizing 
pneumonia  caused  by  serotypes  not 
included in the vaccine has been re-
ported (2). We show an expanded pat-
tern of the changing spectrum of the 
disease associated with nonvaccine se-
rotypes through this report of 4 cases 
of necrotizing pneumonia in children, 
caused by Streptococcus pneumoniae 
serotype 19A.
Over a 6-month period ending in 
March 2008, 4 children (median age 
3.6 years, 1 with asthma) (Table) were 
brought to our hospital with signs of 
respiratory distress and a 4- to 7-day 
history of fever and cough. All had 
decreased  breath  sounds  or  crack-
les,  and  radiologic  studies  showed 
evidence of complicated pneumonia, 
which  led  to  hospital  admission  (3 
to an intensive care unit [ICU]). S. 
pneumoniae  19A  was  isolated  from 
normally sterile sites with each child. 
All  received  intravenous  antimicro-
bial drugs followed by an oral anti-
microbial drug regimen and were dis-
charged in good health. By reviewing 
immunization records, we confirmed 
that all had completed the PCV-7 se-
ries before becoming ill. 
During the same period, compli-
cated pneumonia was identified in 7 
other  inpatients  by  using  the  Inter-
national  Classification  of  Diseases, 
9th  revision,  codes  for  necrotizing 
pneumonia  and  empyema  and  Cur-
rent  Procedural  Terminology  codes 
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